Odactra-Dustmite allergy treatment is available!

For patients with dust mite allergy who are looking to lessen their dust mite allergy symptoms without medication should consider Odactra, a sublingual tablet of concentrated dustmite protein to help teach your body’s immune system to tolerate dust mites. The first dose is taken in the office and then at home! It’s covered by insurance plans. See if you are a candidate, call to make an appointment (703) 558-6040.

Prevent peanut allergy

For infants at high risk, meaning they have eczema, food allergy, sibling with food allergy (especially peanut) or parents with allergies, the LEAP study showed that early introduction of peanut prevented a peanut allergy in most infants.

We offer an evaluation for these high-risk patients and if negative, then we can start patients safely on this preventative therapy and if borderline peanut reaction on allergy skin test, can offer a peanut challenge in the office.

Proper evaluation, dosing and frequency is important to make this therapy successful.

Limitation of testing

A positive allergy test alone does not determine a patient’s allergy status.  The size of skin test and/or level of specific IgE, the patient’s age, specific food and history all go into allowing a board-certified allergist to use their training to determine if a patient has a food allergy.  If needed, an oral challenge may be also utilized to help determine if a patient is truly allergic to a food an not unnecessarily avoiding a food. If your doctor does not offer an oral challenge as a possible option to determine your allergy status then they should not be testing you for allergies. Be educated, a fellowship trained board-certified allergist will be able to provide you the best possible allergy care.


Flu vaccine

Have you had your Influenza vaccine? Updates: the Flumist has been shown not to be effective.  Please get your Flu shot at your primary care physician’s office or local store. Some hospitals such as Adventist have free flu shot days. 

If you have a severe egg allergy and are unable to eat eggs, even a little in baked goods then you much receive your flu vaccine in a medical office under close supervision. Those with severe egg allergy or previous reactions should contact us to schedule a flu vaccine appointment.

For allergen immunotherapy patients, ie allergy shot patients, please wait 48 hrs after your flu shot to receive your allergy shot. If you have a reaction, we won’t know which you are reacting to.

Epiceram -L

Winter is around the corner, Epiceram-L works great to help heal those dry cracked lips.

You can order it online at http://www.epiceram-us.com/epiceram-l

or on Amazon.com

Eucrisa for eczema treatment

Eucrisa is a new treatment for eczema. It is a PDE4 inhibitor. It blocks the inflammatory process involved in eczema. Come in and speak with the allergist to see if it’s right for you.

Indicated for ages 2 and older. Non-steroid medication. Copay cards available.

Pediatric Dupixent trials

Disclaimer: Our office is not affiliated nor endorses any of these clinical trials. We are forwarding information about available clinical trials, it is the patient’s responsibility and due diligence to please review all risks and benefits with the clinical trial researchers prior to participating. 

DermAssociates, PC
Norman A. Lockshin, MD FAAD,FACP
Benjamin N. Lockshin, MD FAAD

Office:  10313 Georgia Avenue,  Suite 309
Silver Spring, Maryland 20902
 Clinical Trials: (301) 355-3183
15245 Shady Grove Road
 www.DermAssociates.com Suite 480 (south entrance)
 Rockville, Maryland 20850

Clinical Trials Center at DermAssociates is currently participating in a Phase 3
clinical research study for adolescent patients with moderate-to-severe atopic dermatitis. We are evaluating the efficacy of an investigational biologic agent called dupilumab which is a fully human monoclonal antibody directed
against IL-4 and IL-13. The results of studies looking at the efficacy and safety of dupilumab for moderate-to-severe
atopic dermatitis were recently published in Lancet 2016; 387: 40-52.
We are actively seeking patients ages ≥ 12-< 18 years of age with moderate-to-severe chronic atopic dermatitis to participate in this new phase 3 study. Eligible patients will be randomized in a 1:1:1 ratio to receive dupilumab or placebo for 12 weeks. The study is expected to demonstrate the efficacy and safety of dupilumab as
a monotherapy in adolescent patients. Patients who participate in the study may subsequently be eligible to participate in an open-label extension study.